All News
Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?
Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).
Read Article
We Measure What we do in RA, But so What?
We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.
Read Article
Does RA kill you? Let me count the ways….and what you can do about it
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
Read ArticleMethotrexate Update
I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.
Read Article
EULAR 2018 - Day 2 Report
Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.
Read Article
Biosimilar Data at #EULAR2018
Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.
Abbvie Highlights Upadacitinib Trials at EULAR18
Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderat
Read Article
EULAR 2018 - Day 1 Report
Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap.
Read Article
Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)
Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.
Read Article
Vedolizumab Implicated in Exacerbations of SpA in IBD Patients
Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.
Read Article
The RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
Read Article
Advance Practice Clinicians Proliferating in Specialty Practices
An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices. By 2016, 28% of all specialty practices employed APCs.
Read Article
FDA Approves Low Dose Baricitinib for Rheumatoid Arthritis
The US Food and Drug Administration has approved baricitinib (Olumiant) for use in adults in moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to TNF inhibitors (TNFi). It is not approved for use, nor has it been studied, in children.
Read Article
FDA Approves Baricitinib 2 mg for Rheumatoid Arthritis
Today the U.S. Food and Drug Administration approved baricitinib (Oluminant) at the lower dose of 2 mg per day for use in adults with with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to commonly-used treatments known as TNF inhibitors.
Read Article
The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)
Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.
Read Article
High anti-TNF Failure Rates with Obesity
A meta-analysis has suggested that obesity is an under-reported predictor of inferior response to tumor necrosis factor blockade (anti-TNF) in a range of inflammatory immune-mediated inflammatory diseases (IMIDs), with the results showing a 60% risk of impaired response to anti-TNF across several
Read Article
Increased Risk of Depression and Anxiety in Rheumatoid Arthritis
Canadian researchers have analyzed population data and shown that the incidence and prevalence of depression, anxiety and bipolar disorders are elevated in the rheumatoid arthritis (RA) patients compared to a matched population.
Read Article
The RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.
Read Article
Treat-to-Target a Bust with Rheumatologists
Treat-to-target strategy is widely advocated as an important means of optimizing treatment responses in patients with rheumatoid arthritis. Even though T2T is encouraged by most guidelines, a current report shows that US Rheumatologists fail to implement T2T in their daily practice.
Read Article
Epigenetic Link in Rheumatoid Arthritis to Huntington's Disease
Researchers at University of California San Diego School and the Icahn School of Medicine have found a high-resolution epigenomic landscape of rheumatoid arthritis (RA) that overlaps with that seen in Huntington's disease, suggesting potentially new unanticipated pathways that could be devel
Read Article
